![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
PK Sonsalla, JW Gibb and GR Hanson
Previous studies have demonstrated that the effects of methamphetamine (METH) on dopaminergic and serotonergic systems are likely related to METH-induced increases in dopamine release. The ability of haloperidol to prevent these effects of METH suggests that dopamine receptor activation is involved in mediating these METH actions. The present studies were undertaken to determine what role the dopamine receptor subtype(s) might have in such METH effects. We found that the D1 antagonist, SCH23390, attenuated or blocked the effects of METH on dopaminergic and serotonergic systems, whereas the D2 antagonist, sulpiride, blocked the effects of METH on only the dopaminergic system. The results of the present studies suggest that METH-induced increases in dopaminergic action on both D1 and D2 receptors are associated with the effects of METH on the dopaminergic system. In contrast, dopamine action on D1, but not on D2, receptors appears to be involved in the effects of METH on the serotonergic systems of the neostriatum and the cerebral cortex.
This article has been cited by other articles:
|
|
 |
|
  K. A. Horner, S. C. Westwood, G. R. Hanson, and K. A. Keefe Multiple High Doses of Methamphetamine Increase the Number of Preproneuropeptide Y mRNA-Expressing Neurons in the Striatum of Rat via a Dopamine D1 Receptor-Dependent Mechanism J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Mark, J.-J. Soghomonian, and B. K. Yamamoto High-Dose Methamphetamine Acutely Activates the Striatonigral Pathway to Increase Striatal Glutamate and Mediate Long-Term Dopamine Toxicity J. Neurosci., December 15, 2004; 24(50): 11449 - 11456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. CADET, S. JAYANTHI, and X. DENG Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis FASEB J, October 1, 2003; 17(13): 1775 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Nordahl, R. Salo, and M. Leamon Neuropsychological Effects of Chronic Methamphetamine Use on Neurotransmitters and Cognition: A Review J Neuropsychiatry Clin Neurosci, August 1, 2003; 15(3): 317 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. LaVoie and T. G. Hastings Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine J. Neurosci., February 15, 1999; 19(4): 1484 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fumagalli, R. R. Gainetdinov, K. J. Valenzano, and M. G. Caron Role of Dopamine Transporter in Methamphetamine-Induced Neurotoxicity: Evidence from Mice Lacking the Transporter J. Neurosci., July 1, 1998; 18(13): 4861 - 4869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Cass Decreases in Evoked Overflow of Dopamine in Rat Striatum after Neurotoxic Doses of Methamphetamine J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 105 - 113. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
